AXSM: Axsome Therapeutics, Inc. Stock

by  •  • Comments Off on AXSM: Axsome Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 6,256.49
Enterprise Value ($M) 6,121.85
Book Value ($M) 57.02
Book Value / Share 1.18
Price / Book 109.73
NCAV ($M) -26.42
NCAV / Share -0.55
Price / NCAV -236.82

Profitability (mra)
Return on Invested Capital (ROIC) -1.16
Return on Assets (ROA) -0.49
Return on Equity (ROE) -1.50

Liquidity (mrq)
Quick Ratio 2.04
Current Ratio 2.11

Balance Sheet (mrq) ($M)
Current Assets 485.06
Assets 568.50
Liabilities 511.48
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 385.69
Operating Income -252.44
Net Income -287.22
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -128.41
Cash from Investing -0.27
Cash from Financing 57.84

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
9 days ago 13G/A Rtw Investments, Lp
2024-02-14 13G/A Fairmount Funds Management LLC 4.90 0.64
2024-02-13 13G/A Vanguard Group Inc 7.81 8.17
2024-01-26 13G/A BlackRock, Inc. 6.80 29.44

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-18 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-05 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-21 282,210 1,356,193 20.81
2025-02-20 104,828 465,836 22.50
2025-02-19 139,028 632,345 21.99
2025-02-18 290,024 1,411,734 20.54

(click for more detail)

Similar Companies
AVBP – ArriVent BioPharma, Inc. AVDL – Avadel Pharmaceuticals plc
AVTE – Aerovate Therapeutics, Inc. BCAB – BioAtla, Inc.
BHST – BioHarvest Sciences Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Axsome Therapeutics